Lung Cancer highlights of ESMO 2023 Congress

Professor Luis Paz-Ares explains the most important novelties in the field of lung cancer treatement after ESMO 2023. - Early stage trails: ADAURA, ALINA, CheckMate 816, Keynote 671, CheckMate 017  - Stage III trial: PACIFIC-6 - STAGE IV trials: LIBRETTO-431, MARIPOSA, MARIPOSA-2, TROPION-Lung01 

Lung cancer highlights of the ESMO 2023 Congress

Professor Benjamin Besse shares his insight on novelties in lung cancer treatment presented at ESMO 2023 Congress. Topics mentioned are targeted therapies, antibody drug conjugates and immunotherapies.

Genitourinary cancer highlights of ESMO 2023 Congress

Silke Gillessen explains the most important stories in GU cancers at ESMO 2023. Studies such as: - EV-302/KEYNOTE-A39 trial: Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy  - CheckMate 901 trial: the first Phase 3 trial with an immunotherapy-based combination to show statistically significant and clinically meaningful survival benefit over standard-of-care cisplatin-based chemotherapy in the first-line treatment of this patient population - PSMAfore: 177Lu-PSMA-617 improves rPFS in taxane-naïve metastatic castration-resistant prostate cancer - RENOTORCH:  a randomized, open-label, phase 3 study of toripalimab combined with axitinib versus sunitinib for the first line treatment of advanced renal cell carcinoma - LITESPARK-005 study: comparing belzutifan to everolimus in patients with previously treated advanced clear cell renal cell carcinoma

RCC highlights of ESMO 2023 Congress

Camillo Porta shares his thoughts about the most important novelties in RCC treatment. Studies such as: - Belzutifan/LITESPARK studies: LITESPARK-003 study of belzutifan in combination with cabozantinib for patients with advanced ccRCC, LITESPARK-005 study comparing belzutifan to everolimus in patients with previously treated advanced ccRCC - Toripalimab/RENOTORCH: a randomized, open-label, phase 3 study of toripalimab combined with axitinib versus sunitinib for the first line treatment of advanced RCC - TIDE-A study: a phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic RCC

Melanoma highlights of ESMO 2023 Congress

Professor Karijn Suijkerbuijk shares with us some highlights from ESMO 2023 on Melanoma. On neoadjuvant treatments of cutaneous melanoma, a small but important study on mucosal melanoma, and novelties on uveal melanoma.

Breast Cancer highlights of the ESMO 2023 Congress

Professor Hope Rugo shares her insights on the breast cancer highlights of #ESMO23 meeting, and also how they apply them in clinical practice. This was a really interesting meeting for breast cancer, we heard a lot of updates about antibody drug conjugates , immunotherapy and endocrine therapy. - DESTINY-Breast04 trial: trastuzumab deruxtecan offers added benefit for patients with HER2-low breast cancer - BEGONIA Phase Ib/II trial: Datopotamab deruxtecan plus Imfinzi demonstrated robust and durable tumour responses in 1st-line treatment of patients with metastatic triple-negative breast cancer - TROPION-Breast01 trial: a phase III trial that investigated datopotamab deruxtecan. - KEYNOTE-522: showed statistically significant and clinically meaningful improvements in pCR and EFS with the addition of pembrolizumab to chemotherapy in patients with early-stage TNBC. - CHECKMATE-7FL: investigating neoadjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy followed by adjuvant nivolumab or placebo plus endocrine therapy.

Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer

Professor Krishnansu Sujata Tewari explains the results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab vedotin demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy. These are the late-breaking results presented at ESMO 2023 congress.

Treatment of mRCC in real world settings

Professor Daniel Heng shares his thoughts on the developments of the last few years in the field of mRCC.

KEYNOTE-942 mRNA-Based vaccine and novel techniques in the field of melanoma

Professor Jeffrey Weber shares his thoughts on the novel techniques in the field of melanoma. Like 5-Year Efficacy and Biomarker Results from CheckMate 238 and KEYNOTE-942, a combination of pembrolizumab plus a novel mRNA-based vaccine based on personalised neoantigens from patients with high-risk resected melanoma.

Late-breaking studies from ESMO 2023

Professor Paweł Sobczuk shares his thoughts on five interesting studies presented during ESMO23. These groundbreaking studies is form different tumor types like breast cancer, lung cancer and prostate cancer.

Data Shows Survival Benefits with Tisotumab Vedotin in Cervical Cancer

Professor Ignace B. Vergote explains the results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab vedotin demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy. These are the late-breaking results presented at ESMO 2023 congress.

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer

Professor Mary McCormack explains the results from the GCIG INTERLACE trial presented in a Presidential Symposium at the ESMO Congress 2023. Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease.

Better use of existing drugs increases cervical cancer survival and reduces recurrence

Professor Krishnansu Sujata Tewari explains the results from he INTERLACE phase 3 trial, assessed whether a short course of induction chemotherapy prior to chemoradiation could reduce the rate of relapse and death among patients with locally advanced cervical cancer. As part of an analysis of clinical data, the preliminary results will be presented at the European Society for Medical Oncology  congress 2023.

Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancer

Professor Filippo Pietrantonio discusses the influence of primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab on KRAS G12C-mutated metastatic colorectal cancer.

Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC

Professor Nicolas Girard explains primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Survival Improved With Nivolumab Plus Chemo in Urothelial Carcinoma

Professor Michiel van der Heijden presented the results of CheckMate 901, a phase III trial evaluating the combination of nivolumab plus gemcitabine/cisplatin versus gemcitabine/cisplatin alone for patients with previously untreated unresectable or metastatic urothelial carcinoma. He shares details on the design of the trial and the late-breaking results that he presented at ESMO 2023.